Vivos Therapeutics, Inc.

VVOS

US92859E2072

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-29 pm EDT			5-day change	1st Jan Change
2.59 ^USD	0.00%		-1.89%	-79.18%

Apr. 01	Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	MT
Apr. 01	Top Premarket Decliners	MT

Vivos Therapeutics, Inc. announced that it has received $4.000003 million in funding

November 01, 2023

On November 2, 2023, Vivos Therapeutics, Inc. closed the transaction.

Latest news about Vivos Therapeutics, Inc.

Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	Apr. 01	MT
Top Premarket Decliners	Apr. 01	MT
Transcript : Vivos Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Vivos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q4 Revenue $3.2M	Mar. 28	MT
Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults	Feb. 06	CI
Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA	Jan. 08	CI
Top Premarket Decliners	Nov. 30	MT
Health Care Drops Amid Skepticism About Cigna, Humana Deal -- Health Care Roundup	Nov. 29	DJ
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 29	MT
Top Midday Gainers	Nov. 29	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Nov. 29	MT
Vivos Therapeutics Receives FDA 510(k) Clearance for Oral Device Treatment for Sleep Apnea; Shares Soar	Nov. 29	MT
Vivos Therapeutics Shares More than Double on FDA's 510(k) Clearance for Sleep Apnea Treatment	Nov. 29	DJ
Upward Revision to Q3 GDP, Dovish Fed Signals Drive Premarket Gains for US Equity Futures	Nov. 29	MT
US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea	Nov. 29	RE
Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea	Nov. 29	CI
Transcript : Vivos Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q3 Revenue $3.3M, vs. Street Est of $4.14M	Nov. 14	MT
Vivos Therapeutics, Inc. announced that it has received $4.000003 million in funding	Nov. 01	CI
Vivos Therapeutics, Inc. announced that it expects to receive $4.000003 million in funding	23-10-29	CI
Vivos Therapeutics Signs Up NOUM as Exclusive Distribution Partner for MENA Region	23-10-05	MT
US Equity Markets Close Higher Wednesday After Ousting of House Speaker	23-10-04	MT
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-04	MT

Chart Vivos Therapeutics, Inc.

Duration

Period

More charts

Vivos Therapeutics, Inc. is a medical technology company. The Company is focused on the development and commercialization of a suit of diagnostic and multi-disciplinary treatment modalities for patients with cranial and/or dentofacial abnormalities and an array of medical conditions, including mild to moderate obstructive sleep apnea (OSA) and snoring in adults. The Company's Vivos Method is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities and/or mild to moderate OSA and snoring. The Company's program is to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice program. The Vivos Method comprises of various products and services, such as Vivos Complete Airway Repositioning and/or Expansion (CARE) oral appliance therapy; VivosGuides; Vivos Versa; POD and Night Block, and VivosMyoCorrect.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Vivos Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.59 USD

Average target price

7.225 USD

Spread / Average Target

+178.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
VIVOS THERAPEUTICS, INC.	-79.18%	7.72M
SHOCKWAVE MEDICAL, INC.	+72.92%	12.36B
PENUMBRA, INC.	-19.68%	7.83B
MASIMO CORPORATION	+16.20%	7.21B
GETINGE AB	+5.26%	5.97B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+7.49%	5.14B
APT MEDICAL INC.	+23.97%	4.43B
ASAHI INTECC CO., LTD.	-18.81%	3.9B
INARI MEDICAL, INC.	-41.54%	2.2B
SKAN GROUP AG	+1.49%	2.02B

Medical Equipment